COMMERCIALIZATION OF INTELLECTUAL ACTIVITY IN THE DESIGN OF DRUGS: CHALLENGES AND SOLUTIONS

With the continuing potential and competitive advantages of Russian science, the listed negative factors and trends create risks for Russia to lag behind the countries that are world’s technological leaders. The above negative factors lead to the depreciation of domestic investments in science and technologies, reduce the independence and competitiveness of Russia in the world, and jeopardize the national security of the country. The paper considers intellectual property protection mechanisms in the state sector of research and development, as well as possible ways of cofinancing a project, including that through venture capital funds. Currently Russia is changing its attitude towards the commercialization of technologies. Russian business schools and the economic faculties of universities pay more and more attention to technology commercialization; there are startups, business incubators, and technology parks. This trend is somewhat weaker in the scientific community, in particular at the university faculties of exact sciences. The authors analyze the problems that arise in the governmental institutions while commercializing the results of intellectual activity, which are obtained from drug design. The authors propose adequate timing solutions. The clinical introduction of the proposed measures to pursue of government policy in science, technology, and innovation will be able to create an ecosystem of high-tech small and medium-sized businesses in pharmaceutics.